Table 1.
Patient characteristics
| Characteristics | Low PC group (%)
|
High PC group (%)
|
P |
|---|---|---|---|
| (n=142) | (n=142) | ||
| Sex | 0.62 | ||
| Male | 96 (67.6) | 91 (64.1) | |
| Female | 46 (32.4) | 51 (35.9) | |
| Age (median, range) years | 56 (23–87) | 53 (19–80) | 0.13 |
| ≤60 | 89 (62.7) | 102 (71.8) | |
| >60 | 53 (37.3) | 40 (28.2) | |
| Primary tumor location | 0.32 | ||
| Right colon | 43 (30.3) | 44 (31.0) | |
| Left colon | 53 (37.3) | 42 (29.6) | |
| Rectum | 46 (32.4) | 56 (39.4) | |
| Pathological type | 0.24 | ||
| Well differentiated | 3 (2.1) | 0 (0) | |
| Moderately differentiated | 93 (65.5) | 84 (59.2) | |
| Poorly differentiated | 29 (20.4) | 35 (24.6) | |
| Mucinous adenocarcinoma | 14 (9.9) | 21 (14.8) | |
| Unknowna | 3 (2.1) | 2 (1.4) | |
| Pathologic tumor classification | 0.37 | ||
| T1 | 2 (1.4) | 2 (1.4) | |
| T2 | 2 (1.4) | 7 (5.0) | |
| T3 | 24 (16.9) | 26 (18.3) | |
| T4 | 114 (80.3) | 105 (73.9) | |
| Unknownb | 0 (0) | 2 (1.4) | |
| Lymphatic invasion | 101 | 100 | 0.9 |
| Vascular invasion | 10 (7.0) | 16 (11.3) | 0.3 |
| Perineural invasion | 2 (1.4) | 6 (4.3) | 0.17 |
| First-line bevacizumab therapy | 0.38 | ||
| With bevacizumab | 26 (18.3) | 33 (23.2) | |
| Without bevacizumab | 116 (81.7) | 109 (76.8) | |
| First-line chemotherapy regimen | 0.31 | ||
| Oxaliplatin-based | 110 (77.5) | 103 (72.5) | |
| Irinotecan-based | 23 (16.2) | 30 (21.1) | |
| Fluorouracil alone | 1 (0.7) | 4 (2.8) | |
| Oxaliplatin plus irinotecan | 8 (5.6) | 5 (3.5) |
Notes:
a
Five patients pathologically diagnosed with colorectal adenocarcinoma without the differentiation degree by the biopsy specimen or pathology consultation of specimen from other hospitals.
b
There was no surgical primary tumor specimen from these patients.
Abbreviation: PC, perivascular cell coverage.